Videos

Jacinta M. Behne, MA, describes how the Guthy-Jackson Charitable Foundation supports patients with neuromyelitis optica spectrum disorders.

Following her presentation at MDS 2021, the PhD candidate in epidemiology at Erasmus University Medical Center discussed highlights from this year’s virtual congress. [WATCH TIME: 2 minutes]

Episode 15 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas. [WATCH TIME: 4 minutes]

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed whether omaveloxolone’s therapeutic benefit is enough for it to become the first approved therapy for Friedrich ataxia. [WATCH TIME: 2 minutes]

The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]

The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending September 25, 2021. [WATCH TIME: 4 minutes]

An overview of fumarates available as treatment for relapsing multiple sclerosis and recommendations for counseling and caring for patients on these therapies.

Considerations for using anti-CD20 therapies versus other available treatment options for relapsing multiple sclerosis.

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed his presentation at MDS 2021, which highlighted the therapeutic benefit of omaveloxolone in Friedreich ataxia. [WATCH TIME: 2 minutes]

When asked about developments, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel commented on the need to identify disease-modifying therapies. [WATCH TIME: 3 minutes]

The director of the Women’s Prevention Center at Cleveland Clinic discussed why understanding genetics may help drug development of Alzheimer disease treatments. [WATCH TIME: 2 minutes]

Following his presentation at the MDS Society Virtual Congress 2021, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center discussed his views on the use of medical cannabis. [WATCH TIME: 3 minutes]

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center discussed future neuroimaging projects the center is evaluating and where the focus turns to next. [WATCH TIME: 3 minutes]

Next steps for medical cannabis will need to include how cannabinoids affect the brain, according to the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel.

The director of The Women’s Alzheimer’s Movement Prevention Center at Cleveland Clinic discussed her recently awarded NIH grant and her work to understand why women are more likely to be impacted by Alzheimer disease.

Doug and Kim, patients with neuromyelitis optica spectrum disorders, describe the types of symptoms that prompted each of them to seek an evaluation by a neurologist for an eventual diagnosis of a neuromyelitis optica spectrum disorder.

Mayo Clinic’s Brian G. Weinshenker, MD, compares multiple sclerosis with neuromyelitis optica spectrum disorders (NMOSD) and explains why community neurologists need to receive more education on NMOSD risk factors and symptoms.

The neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel discussed future use of medical cannabis and concerns for psychiatric adverse effects.

The neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel outlined the small, retrospective study, shedding light on its findings.

The professor of neurology at Weill Cornell Medical School commented on the available treatments for Parkinson disease, as well as ongoing therapeutic development.

Neurology News Network for the week ending September 18, 2021.

The president of the American Academy of Sleep Medicine emphasized the need to prioritize sleep for children and the organization’s efforts to improve sleep health.

An overview of clinical trial data supporting the use of ocrelizumab and ofatumumab as treatment options for patients with relapsing multiple sclerosis.

Variables that impact which S1P receptor modulator is selected as treatment for relapsing multiple sclerosis.

The director of the Movements Disorders Clinic at Houston Methodist Neurological Institute discussed data presented at the International Parkinson and Movement Disorders Society Virtual Congress 2021.

The director of the division of vascular neurology at the University of Utah discussed ongoing efforts from the AAN, as well as the potential to integrate advanced practice providers into neurology teams.

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided a realistic perspective of when and how AI will be incorporated into the wider medical system.

This series is brought to you by a partnership between NeurologyLive, the Consortium of Multiple Sclerosis Centers (CMSC), and the International Organization of Multiple Sclerosis Rehabilitation Therapists (IOMSRT).

The associate professor of neurology at Washington University in St. Louis discussed the latest initiative from the AASM, emphasizing sleep health for school-aged children.